Abstract
AbstractAs our understanding of the mechanisms of cancer treatment has increased, a growing number of studies demonstrate pathways through which DNA damage repair (DDR) affects the immune system. At the same time, the varied response of patients to immune checkpoint blockade (ICB) therapy has prompted the discovery of various predictive biomarkers and the study of combination therapy. Here, our investigation explores the interactions involved in combination therapy, accompanied by a review that summarizes currently identified and promising predictors of response to immune checkpoint inhibitors (ICIs) that are useful for classifying oncology patients. In addition, this work, which discusses immunogenicity and several components of the tumor immune microenvironment, serves to illustrate the mechanism by which higher response rates and improved efficacy of DDR inhibitors (DDRi) in combination with ICIs are achieved.
Funder
Natural Science Foundation of Guangdong Province
Innovative Research Group Project of the National Natural Science Foundation of China
Science and Technology Planning Project of Guangdong Province
Publisher
Springer Science and Business Media LLC
Reference252 articles.
1. Marconcini R, Spagnolo F, Stucci LS, Ribero S, Marra E, de Rosa F, et al. Current status and perspectives in immunotherapy for metastatic melanoma. Oncotarget. 2018;9:12452–70 Impact Journals LLC. Available from: https://pubmed.ncbi.nlm.nih.gov/29552325. Accessed 11 Aug 2021.
2. Si Y, Lin A, Ding W, Meng H, Luo P, Zhang J. CARD11 alteration as a candidate biomarker of skin cutaneous melanoma treated with immune checkpoint blockade. Am J Transl Res. 2021;13:286–300 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847528/. Accessed 15 June 2022.
3. Lin W, Lin A, Li Z, Zhou C, Chen C, Chen B, et al. Potential predictive value of SCN4A mutation status for immune checkpoint inhibitors in melanoma. Biomed Pharmacother. 2020;131:110633 Available from: http://www.ncbi.nlm.nih.gov/pubmed/32892029. Accessed 14 June 2022.
4. Nolan E, Savas P, Policheni AN, Darcy PK, Vaillant F, Mintoff CP, et al. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Sci Transl Med. 2017;9 Available from: http://stm.sciencemag.org/. Accessed 9 Sept 2021.
5. Parker C. A near miss for prostate cancer immunotherapy. Lancet Oncol. 2014;15:669–71 Available from: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70220-7/fulltext. Accessed 7 Sept 2021.
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献